ExeGi Pharma announces probiotic Visbiome clinical trial in MS patients

Visbiome clinical trial : ExeGi Pharma said that researchers at Columbia University Irving Medical Center and the University of Pittsburgh will be studying the company’s probiotic product Visbiome in multiple sclerosis (MS) patients in a new clinical trial.

The clinical trial will look into the effects of probiotics on the gut microbiota and immune systems of such patient population.

A previously held study, the findings of which were published in Annals of Neurology last year, demonstrated that administration of the probiotic led to changes in the composition of gut microbiota in multiple sclerosis patients apart from increasing anti-inflammatory biomarkers.

The new Visbiome clinical trial in MS patients will explore the outcomes further with an aim to determine if targeting the microbiome can offer a therapeutic strategy for multiple sclerosis patients.

Visbiome clinical trial in MS patients to be held by Columbia University Irving Medical Center and the University of Pittsburgh researchers. Photo courtesy of ExeGi Pharma.

Marc Tewey – CEO of ExeGi Pharma, commenting on the Visbiome clinical trial in MS patients, said: “We are excited about this opportunity to expand upon the available information on the effects of probiotics in multiple sclerosis patients. The probiotic formulation in Visbiome has been the subject of over 70 human clinical studies, including a preliminary study in 2018 in MS patients.

“The findings of this new study will be beneficial for the scientific community as a whole by contributing important information about the complex relationship between the microbiome and immune system.”

According to ExeGi Pharma, Visbiome is a high probiotic made up of eight strains of live, freeze-dried lactic acid bacteria.

The probiotic product is a medical food developed for the dietary management of dysbiosis related to ulcerative colitis, irritable bowel syndrome (IBS), pouchitis, and hepatic encephalopathy. ExeGi Pharma claims that Visbiome is a non-drug therapy that addresses distinct nutritional requirements, to promote microbial balance, in people with such disorders.

Rebecca Farber – Columbia University Vagelos College of Physicians and Surgeons assistant professor of neurology, and one of the lead researchers on the Visbiome clinical trial in MS patients, said: “The gut microbiome plays an important role in modulating the immune system, which is dysregulated in individuals with MS. This study will enhance our understanding about whether probiotics may be able to advantageously reshape the immune system and prevent degeneration of the nervous system.”

Related posts

• Boehringer Ingelheim bags Ofev FDA approval for SSc-ILD (0)
• BioMed, University of California open cancer research center in San Diego (0)
• Maruho, X-Chem collaborate to advance drug discovery (0)
• OncoCyte to acquire Razor Genomics to advance lung cancer diagnosis (0)
• Vertex to acquire Semma Therapeutics to advance stem cell-based treatments for type 1 diabetes (0)
• Puma secures FDA orphan drug status for NERLYNX in breast cancer with brain metastases (0)
• Fresenius Kabi launches Phenylephrine Hydrochloride Injection, USP in US (0)
• Boston Scientific wraps up $4.2bn acquisition of BTG (0)
• MERU clinical trial : AbbVie ends Rova-T program in lung cancer (0)
• Kyowa Kirin’s Nourianz cleared for use in Parkinson’s disease in US (0)

The post ExeGi Pharma announces probiotic Visbiome clinical trial in MS patients appeared first on PharmaNewsDaily.com.